Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Regeneron Pharmaceuticals ... with estimated sales of $17 billion. From Q4 2024 results, Dupixent revenue increased by 15% year-on-year, and with these extensions, I can foresee positive growth ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per ...

We subsequently announced a clinical trial supply agreement with Regeneron for Libtayo in combination with IMM-1-104 in patients with non-small cell lung cancer and aim to get these new trials up ...

Regeneron reported Q4 2024 EPS of $12.07, beating consensus estimates by 71 cents. Revenues rose 10.3% YoY to $3.79 billion, beating $3.74 billion consensus analyst estimates. Non-GAAP net income ...

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm expects a “messy” Q1 report for Eylea but sees the ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Looking at Natera’s peers in the immuno-oncology segment, some have already reported their Q4 results ... analysts’ expectations by 1.6%, and Regeneron reported revenues up 10.3%, topping ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...